Immunopathology of vitiligo: A Review of literature

A E Silva; L Castoldi

doi:10.36560/722014133

Autores

A E Silva Federal University of Mato Grosso, Sinop
L Castoldi Federal University of Mato Grosso, Sinop

DOI:

https://doi.org/10.36560/722014133

Palavras-chave:

vitiligo; immunopathology, autoimunnity

Resumo

Vitiligo is a morbidity characterized by depigmentation of body parts from the loss or reduction of melanocytes. The disease affects an average of 1% of the world population, usually individuals with mean age of 20, affecting both men and women regardless of race. Within existing therapies, there are many treatments being offered, however, improvements upon treatments vary from person to person and cure is rare to obtain. The etiology of vitiligo is still not clear, there are many hypothesis for his cause. Then, this study aimed to review literature regarding the latest immunological mechanisms involved in the onset of vitiligo.

Biografia do Autor

L Castoldi, Federal University of Mato Grosso, Sinop

INSTITUTO DE CIÃŠNCIAS DA SAÃšDE, UNIVERSIDADE FEDERAL DE MATO GROSSO

ÃREA: IMUNOLOGIA

Referências

ANTELO, DP., FILGUEIRA, AL., CUNHA, JMT. Aspectos imunopatológicos do vitiligo.Med. Cutan. Iber. Lat. Am.36: 125-136, 2008.aANTELO, DP., FILGUEIRA, AL., CUNHA, JMT. Redução dos linfócitos T-CD8+citotóxicos observada com a terapia Puva em paciente com vitiligo. An. Bras. Dermatol. 83: 572-574, 2008.

BARROS, JA., Machado Filho, CD’AS., MARTINS, LC., PETTINATI, J., PINHAL, MAS. Vitiligo: avaliação histológica e clínica após curetagem seqüencial. An. Bras. Dermatol. 82: 327-335, 2007.

BASAK, PY., ADILOGLU, AK., CEYHAN, AM., TAS, T., AKKAYA, AB. The role of helper and regulatory T cells in the pathogenesis of vitiligo. Journal of the American Academy of Dermatology60: 256-260, 2009.

BASSIOUNY, D., SHAKER, O. Role of interleukin-17 in the pathogenesis of vitiligo. Clinical and Experimental Dermatology36: 292-297, 2010.

BOORN, JGVD., Konijnenberg, D., Dellemijn, TAM., van der Veen, JPW., Bos, JD., Melief, CJM., Vyth-Dreese, FA., Luiten, RM. Autoimmune destruction of skin melanocytes by perilesionalT cells from vitiligo patients. Journal of Investigative Dermatology129: 2220-2232, 2009.

BUDEL, AR., GOMES, AMG., GONÇALVES, ACS., JORDÃO, JM., OSSOWSKI, AC., SKARE, TL. Associação entre vitiligo e doenças auto-imunes: prevalência no Serviço de Dermatologia do Hospital Universitário Evangélico de Curitiba. Arquivos Catarinenses de Medicina, Paraná 35: 66-70, 2006.

CASARA, C., EIDT, L., CUNHA, V. Prevalence study of dermatoses referred to the phototherapy unit at the Dermatology Service of the Clinics Hospital of Porto Alegre, RS, Brazil. An. Bras.Dermatol. 88: 211-215, 2013.

DANESHPAZHOOH, M., MOSTOFIZADEH G, M., BEHJATI, J., AKHYANI, M., ROBATI, RM. Anti-thyroid peroxidase antibody and vitiligo: a controlled study. BMC Dermatology6: 1-5, 2006.

DWIVEDI, M.,LADDHA, NC.,ARORA, P.,MARFATIA, YS,BEGUM, RDecreased regulatory T-cells and CD4+/CD8+ ratio correlate with disease onset and progression in patients with generalized vitiligo. Pigment Cell Melanoma26: 586-591, 2013.

ESMAEILI, B.,REZAEE, SA.,LAYEGH, P.,TAVAKKOL AFSHARI, J.,DYE, P.,GHAYOOR KARIMIANI, E,KALALINIA, F.,RAFATPANAH, H.Expression of IL-17 and COX2 Gene in Peripheral Blood Leukocytes of Vitiligo Patients. Iran J. Allergy Asthma Immunol. 10: 81-89, 2011.

FARROKHI, S,HOJJAT-FARSANGI, M.,NOOHPISHEH, MK,TAHMASBI, R.,REZAEI, N. Assessment of the immune system in 55 Iranian patients with vitiligo. J.Eur.Acad.Dermatol.Venereol.19: 706-711, 2005.GEEL NV.,SPEECKAERT, M.,BROCHEZ, L.,LAMBERT, J.,SPEECKAERT, R.Clinical profile 118

Silva and Castoldi et al. Immunopathology of Vitiligo: A Review of Literatureof generalized vitiligo patients with associated autoimmune/autoinflammatory diseases. J. Eur.Acad.Dermatol.Venereol.28:741-6, 2013.

GOPAL, KV.,RAMA RAO, GR.,KUMAR, YH.,APPA RAO, MV.,VASUDEV, PS.Vitiligo: A part of a systemic autoimmune process. Indian J.Dermatol .Venereol.Leprol.73: 162-165, 2007.

HARTMANN, A., BRÖCKER, EB., BECKER, JC.Hypopigmentary skin disorders: current treatment options and future directions. Drugs64: 89-107, 2004.

HOLLA, AP., SAHNI, P., KUMAR, R., PARSAD, D., KANWAR, A., MEHTA, SD. Acral vitiligoand lesions over joints treated with non-cultured epidermal cell suspension transplantation. Clinical and Experimental Dermatology38: 332-337, 2013.

KEMP, EH.Autoantibodies as Diagnostic and Predictive Markers of Vitiligo.Autoimmunity37: 287-290, 2004.MACHADO FILHO, CDAS., ALMEIDA, FA., PROTO, RS., LANDMAN, G. Vitiligo: analysis of grafting versus curettage alone, using melanocyte morphology and reverse transcriptase polymerase chain reaction for tyrosinase mRNA. São Paulo Med.J.123: 187-91, 2005.

MANDELCORN-MONSON, RL., SHEAR, NH., YAU, E., SAMBHARA, S., BARBER, BH., SPANER, D., DEBENEDETTE, MA. Cytotoxic T Lymphocyte Reactivity to gp100, MelanA/MART-1,and Tyrosinase, in HLA-A2-PositiveVitiligo Patients. The Journal of Investigative Dermatology121; 550-556, 2003.

MANGA, P., ORLOW,SJ. Engineering a new mouse model for vitiligo. The Journal of Investigative Dermatology132: 1752-1755, 2012.

MANTOVANI, S., GARBELLI, S., PALERMO, B., CAMPANELLI, R., BRAZZELLI, V., BORRONI, G., MARTINETTI, M., BENVENUTO, F., MERLINI, G., CUNA, GR., RIVOLTINI, L., GIACHINON, C. Molecular and Functional Bases of Self-Antigen Recognition in Long-Term Persistent Melanocyte-Specific CD8+T Cells in One Vitiligo Patient. The Journal of Investigative Dermatology 12: 308-314, 2003.

MONTES, LF.,ABULAFIA, J.,WILBORN, WH.,HYDE, BM.,MONTES, CM.Value of histopathology in vitiligo. Int. J. Dermatol. 42: 57-61, 2003.

MOSENSON, JA., ZLOZA, A., KLARQUIST, J., BARFUSS, AJ., GUEVARA-PATINO, JA., LE POOLE, C. HSP70i is a critical component of the immune response leading to vitiligo. Pigment Cell Melanoma Res. 25: 88-98, 2012.

NAI, GA., MIOT, LBD., MIOT, HA., MARQUES, MEA.Imuno-histoquímica para diagnóstico precoce de vitiligo.J.Bras.Patol.Med.Lab. 44: 367-373, 2008.

NUNES, DH., ESSER, LMH. Perfil epidemiológico dos pacientes com vitiligo e sua associação com doenças da tireoide.An. Bras.Dermatol. 86: 241-248, 2011.

ONGENAE, K., GEEL, NV., NAEYAERT, JM.Evidence for an Autoimmune Pathogenesis of Vitiligo.Pigment Cell Res. 16: 90-100, 2003.

PARSAD, D., PANDHI, R., DOGRA,S., KUMAR,B. Clinical study of repigmentationpatterns with different treatment modalities and their correlation with speed and stability of repig mentation in 352 vitiliginous patches. J.Am.Acad.Dermatol.50: 63-67, 2004.

PICHLER, R.,SFETSOS, K.,BADICS, B.,GUTENBRUNNER, S.,BERG, J.,AUBÖCK, J. Lymphocyte imbalance in vitiligo patients indicated by elevated CD4C/CD8C T-cell ratio. Wien Med Wochenschr159: 337-341, 2009.

Silva and Castoldiet al. Immunopathology of Vitiligo: A Review of LiteratureSALDANHA, KDD., MACHADO FILHO, CD'AS., PASCHOAL, FM. Ação da mometasona tópica nos halos pigmentares de microenxertia em vitiligo.An. Bras. Dermatol. 87: 685-690, 2012.

SINGH, ZN,TRETIAKOVA, MS.,SHEA, CR.,PETRONIC-ROSIC, VMDecreased CD117 expression in hypopigmented mycosis fungoides correlates with hypomelanosis: lessons learned from vitiligo. Modern Pathology 19: 1255-1260, 2006.

SOUZA FILHO, LGC., RIVITTI, EA., MIYAUCHI, LM., SOTTO, MN., MARIA, DA., PUEJO, SST., ALVES, VAF. Estudo comparativo entre vitiligo, nevo halo e lúpus eritematoso vitiligóide por meio de métodos imunológicos, histológicos e imuno-histoquímicos.An. Bras.Dermatol. 80: 143-148,2005.

SOUZA, APFS., CARVALHO, FT., ROCHA, KB., LAGES, MN., CALVETTI, Pü., CASTOLDI, L. Associação de eventos estressores ao surgimento ou agravamento de vitiligo e psoríase.PSICO36: 167-174, 2005.

SPEECKAERT, R., GEEL,NV. Distribution patterns in generalized vitiligo. J. Eur. Acad. Dermatol. Venereol.28: 755-762, 2014.

TEMBHRE, MK.,SHARMA, VK.,SHARMA, A.,CHATTOPADHYAY, P.,GUPTA, S.T helper and regulatory T cell cytokine profile in active, stable and narrow band ultraviolet B treated generalized vitiligo. Clinica ChimicaActa424: 27-32, 2013.

YAMAGUCHI, Y., HEARING, VJ. Melanocytes and their diseases. Cold Spring Harb Perspect Med. 4: 1-18, 2014